Antiretroviral drug resistance in human immunodeficiency virus-infected source patients for occupational exposures to healthcare workers.
OBJECTIVE
To assess the prevalence of HIV antiretroviral resistance among source patients for occupational HIV exposures.


METHODS
Blood and data (eg, stage of HIV, previous antiretroviral drug therapy, and HIV RNA viral load) were collected from HIV-infected patients who were source patients for occupational exposures.


METHODS
Seven tertiary-care medical centers in five U.S. cities (San Diego, California; Miami, Florida; Boston, Massachusetts; Albany, New York; and New York, New York [three sites]) during 1998 to 1999.


METHODS
Sixty-four HIV-infected patients who were source patients for occupational exposures.


RESULTS
Virus from 50 patients was sequenced; virus from 14 patients with an undetectable (ie, < 400 RNA copies/mL) viral load could not be sequenced. Overall, 19 (38%) of the 50 patients had primary genotypic mutations associated with resistance to reverse transcriptase or protease inhibitors. Eighteen of the 19 viruses with primary mutations and 13 wild type viruses were phenotyped by recombinant assays; 19 had phenotypic resistance to at least one antiretroviral agent. Of the 50 source patients studied, 26 had taken antiretroviral agents in the 3 months before the occupational exposure incident. Sixteen (62%) of the 26 drug-treated patients had virus that was phenotypically resistant to at least one drug. Four (17%) of 23 untreated patients had phenotypically resistant virus. No episodes of HIV transmission were observed among the exposed HCWs.


CONCLUSIONS
There was a high prevalence of drug-resistant HIV among source patients for occupational HIV exposures. Healthcare providers should use the drug treatment information of source patients when making decisions about post-exposure prophylaxis.
Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Elise M
EM
Beltrami
Rachanee
R
Cheingsong
Walid M
WM
Heneine
Richard A
RA
Respess
Jean G
JG
Orelien
Meryl H
MH
Mendelson
Mari A
MA
Stewart
Brian S
BS
Koll
Carol A
CA
Sulis
Denise M
DM
Cardo
D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics*; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000635:transmission / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006282:Health Personnel; D006801:Humans; D017758:Infectious Disease Transmission, Patient-to-Professional / Q000517:prevention & control; D016273:Occupational Exposure / Q000009:adverse effects* / Q000032:analysis; D010641:Phenotype; D015995:Prevalence; D014481:United States
D019380:Anti-HIV Agents